NAGAILEBEN CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,479 JPY | -0.88% |
|
+2.31% | +4.07% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The group's high margin levels account for strong profits.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company benefits from high valuations in earnings multiples.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts recommend that the stock should be sold or reduced.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.07% | 505M | - | ||
| +7.98% | 26.99B | B+ | ||
| -42.05% | 2.63B | B- | ||
| +25.19% | 2.44B | B | ||
| -23.19% | 2.31B | C+ | ||
| +5.99% | 2.21B | - | A- | |
| +22.22% | 1.87B | B | ||
| +32.97% | 1.33B | C | ||
| +30.76% | 1.37B | B | ||
| +0.38% | 1.3B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
-
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 7447 Stock
- Ratings Nagaileben Co., Ltd.
